Arcadia Biosciences Inc (RKDA) Q3 2024 Earnings Report Preview: What To Look For

Author's Avatar
Nov 07, 2024
Article's Main Image

Arcadia Biosciences Inc (RKDA, Financial) is set to release its Q3 2024 earnings on Nov 8, 2024. The consensus estimate for Q3 2024 revenue is $1.40 million, and the earnings are expected to come in at -$0.81 per share. The full year 2024's revenue is expected to be $5.25 million and the earnings are expected to be -$1.41 per share. More detailed estimate data can be found on the Forecast page.

Arcadia Biosciences Inc (RKDA, Financial) Estimates Trends

Over the past 90 days, revenue estimates for Arcadia Biosciences Inc (RKDA) have increased from $4.91 million to $5.25 million for the full year 2024, and from $6.39 million to $6.53 million for 2025. Earnings estimates have declined from -$1.35 per share to -$1.41 per share for the full year 2024, and have increased from -$1.81 per share to -$1.28 per share for 2025.

Arcadia Biosciences Inc (RKDA, Financial) Reported History

In the previous quarter of June 30, 2024, Arcadia Biosciences Inc's (RKDA) actual revenue was $1.31 million, which beat analysts' revenue expectations of $0.93 million by 41.19%. Arcadia Biosciences Inc's (RKDA) actual earnings were $0.78 per share, which missed analysts' earnings expectations of $1.55 per share by -49.68%. After releasing the results, Arcadia Biosciences Inc (RKDA) was down by -11.04% in one day.

1854497222897594368.png

Arcadia Biosciences Inc (RKDA, Financial) 12 Month Price Targets

Based on the one-year price targets offered by 2 analysts, the average target price for Arcadia Biosciences Inc (RKDA) is $9 with a high estimate of $12 and a low estimate of $6. The average target implies an upside of 116.35% from the current price of $4.16.

Based on GuruFocus estimates, the estimated GF Value for Arcadia Biosciences Inc (RKDA, Financial) in one year is $3.25, suggesting a downside of -21.88% from the current price of $4.16.

Based on the consensus recommendation from 2 brokerage firms, Arcadia Biosciences Inc's (RKDA, Financial) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

1854497369295581184.png

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.